9969 — InnoCare Pharma Income Statement
0.000.00%
Last trade - 00:00- HK$26.52bn
- HK$20.10bn
- CNY2.37bn
Annual income statement for InnoCare Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,043 | 625 | 739 | 1,009 | 2,375 |
| Cost of Revenue | |||||
| Gross Profit | 977 | 482 | 610 | 871 | 2,184 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,064 | 1,519 | 1,390 | 1,461 | 1,719 |
| Operating Profit | -21.5 | -893 | -651 | -451 | 655 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20.1 | -894 | -644 | -453 | 656 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -66.7 | -894 | -646 | -453 | 644 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -64.5 | -887 | -631 | -441 | 642 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -64.5 | -887 | -631 | -441 | 642 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.037 | -0.503 | -0.37 | -0.26 | 0.38 |
| Dividends per Share |